One in four fatal crashes now involves a driver who tested positive for drugs. Cannabis is the most common substance detected. The legal landscape has shifted dramatically, but reliable impairment testing remains a complex challenge.
Key Takeaways
- In 2021, 16 states and Washington, D.C. had legalized recreational adult-use cannabis (as reported by NCSL).
- In 2024, 25 states had legalized adult-use cannabis for adults (as summarized by NCSL).
- As of 2024, 38 states and Washington, D.C. had legalized medical cannabis (as summarized by NCSL).
- In 2021, NHTSA estimated 14.1% of drivers involved in crashes tested positive for drugs, with cannabis being the most common drug (NHTSA analysis).
- In 2020, the WHO reported that “traffic injury” is a leading cause of death globally, with 1.19 million road deaths per year (background for road-safety impacts).
- About 19% of U.S. drivers in 2021 reported using cannabis in the past year (NHTSA estimates from survey data; “Traffic Safety Facts”).
- $8.6 billion in federal-aid highway safety programs were obligated in FY 2022 (FHWA safety program funding overview).
- $50.2 billion of U.S. substance use disorder economic costs in 2017 were attributable to illicit drugs (CDC).
- In a 2021 study, average costs of DUI enforcement and processing were estimated at roughly $1,000 per case (varies by jurisdiction; DUI case-processing cost analysis).
- In 2023, North America accounted for the largest share of the global cannabis market at 46% (industry estimate).
- That same 2023 report projected the roadside drug testing market to reach $4.7 billion by 2028 (market growth projection).
- The oral fluid drug testing market was estimated at $2.5 billion in 2023 and projected to reach $5.8 billion by 2028 (market sizing for impairment testing).
- In the same 2020 study, specificity for THC screening was often above 90% at commonly used screening cutoffs (peer-reviewed diagnostic performance).
- A 2019 systematic review found that oral-fluid immunoassays for THC had heterogeneous performance and that confirmatory GC/MS testing was required for evidentiary accuracy in most settings.
- A 2018 validation study reported that the analytical measurement range for THC in oral fluid assays covered concentrations from 1 to 1000 ng/mL (assay validation parameters).
With more legalization and high THC exposure rates, accurate testing and enforcement remain crucial for safer roads.
Related reading
01 · Category
Policy & Regulation4 stats
01
In 2021, 16 states and Washington, D.C. had legalized recreational adult-use cannabis (as reported by NCSL).
02
In 2024, 25 states had legalized adult-use cannabis for adults (as summarized by NCSL).
03
As of 2024, 38 states and Washington, D.C. had legalized medical cannabis (as summarized by NCSL).
04
21 states plus D.C. had implemented “zero tolerance” or other “any measurable amount” approaches to marijuana in driving laws as reported by NCSL’s compilation of state laws.
Interpretation
Policy & Regulation Interpretation
From a policy and regulation standpoint, cannabis laws are rapidly expanding with adult-use legalization rising from 16 states plus Washington, D.C. in 2021 to 25 states by 2024, while medical legalization reaches 38 states plus Washington, D.C., alongside stricter driving enforcement with 21 states plus D.C. adopting zero tolerance or any measurable amount approaches.
02 · Category
Crash & Epidemiology3 stats
01
In 2021, NHTSA estimated 14.1% of drivers involved in crashes tested positive for drugs, with cannabis being the most common drug (NHTSA analysis).
02
In 2020, the WHO reported that “traffic injury” is a leading cause of death globally, with 1.19 million road deaths per year (background for road-safety impacts).
03
About 19% of U.S. drivers in 2021 reported using cannabis in the past year (NHTSA estimates from survey data; “Traffic Safety Facts”).
Interpretation
Crash & Epidemiology Interpretation
From a Crash and Epidemiology perspective, the share of drivers testing positive for drugs in crashes was 14.1% in 2021, with cannabis the most common, while broader context shows traffic injuries cause 1.19 million road deaths globally each year and about 19% of US drivers reported cannabis use in the past year in 2021.
03 · Category
Cost Analysis4 stats
01
$8.6 billion in federal-aid highway safety programs were obligated in FY 2022 (FHWA safety program funding overview).
02
$50.2 billion of U.S. substance use disorder economic costs in 2017 were attributable to illicit drugs (CDC).
03
In a 2021 study, average costs of DUI enforcement and processing were estimated at roughly $1,000per case (varies by jurisdiction; DUI case-processing cost analysis).
04
0.1% annual compounding rate in traffic-safety enforcement costs is referenced as typical program cost growth in a 2020 DOT safety economic review (context for cost planning).
Interpretation
Cost Analysis Interpretation
In the Cost Analysis of Marijuana DUI, federal highway safety funding totaling $8.6 billion in FY 2022 underscores the scale of investment, while DUI enforcement and processing averaging about $1,000 per case and typical enforcement cost growth at a 0.1% annual compounding rate suggest that even relatively small per-case and growth factors can add up against the broader $50.2 billion in 2017 illicit drug economic costs.
04 · Category
Industry Trends5 stats
01
In 2023, North America accounted for the largest share of the global cannabis market at 46% (industry estimate).
02
That same 2023 report projected the roadside drug testing market to reach $4.7 billion by 2028 (market growth projection).
03
The oral fluid drug testing market was estimated at $2.5 billion in 2023 and projected to reach $5.8 billion by 2028 (market sizing for impairment testing).
04
In 2022, the global breath alcohol testing device market was valued at $2.4 billion (market sizing for impairment enforcement technology).
05
By 2030, the cannabis testing market was projected to exceed $10.5 billion (industry estimate).
Interpretation
Industry Trends Interpretation
Industry Trends data shows that as North America led the cannabis market with a 46% share in 2023, demand for impairment and cannabis-related testing is also accelerating, with the roadside drug testing market projected to grow to $4.7 billion by 2028 and the cannabis testing market expected to exceed $10.5 billion by 2030.
05 · Category
Technology & Diagnostics10 stats
01
In the same 2020 study, specificity for THC screening was often above 90% at commonly used screening cutoffs (peer-reviewed diagnostic performance).
02
A 2019 systematic review found that oral-fluid immunoassays for THC had heterogeneous performance and that confirmatory GC/MS testing was required for evidentiary accuracy in most settings.
03
A 2018 validation study reported that the analytical measurement range for THC in oral fluid assays covered concentrations from 1 to 1000 ng/mL (assay validation parameters).
04
A 2021 lab study found that THC concentrations in oral fluid declined with time after smoking, with median detection windows typically under 12 hours depending on method and exposure level.
05
In 2020, a forensic toxicology review estimated that saliva/oral fluid THC detection time after cannabis smoking could be up to about 24 hours in some cases (review).
06
A 2017 peer-reviewed study reported that whole blood THC concentrations often correlate modestly with impairment measures, with correlation coefficients typically in the 0.2–0.4 range (reviewed evidence).
07
A 2020 paper on impairment biomarkers reported that active THC metabolite 11-OH-THC was detectable in blood in a time window consistent with recent use in many cases, improving interpretability compared with THC alone (forensic tox evidence).
08
A 2022 study found that passive exposure to cannabis could yield detectable THC in oral fluid at low levels in some scenarios, potentially affecting screening results (study on false positives).
09
A 2019 study reported that confirmatory testing with GC/MS is necessary to distinguish true THC positives from interferents in immunoassays (forensic diagnostic guidance).
10
A 2016 study reported that THC in blood measured by immunoassay screening required confirmatory LC-MS/MS due to cross-reactivity and variability (forensic testing).
Interpretation
Technology & Diagnostics Interpretation
Across Technology and Diagnostics research, THC testing in oral fluid and related specimens shows that while screening specificity in a 2020 study is often above 90% at common cutoffs, real-world assay performance can vary widely and detection windows after smoking can extend toward about 24 hours, with 2019 and 2018 studies reflecting heterogeneous immunoassay performance and measurement ranges spanning roughly 1 to 1000 ng/mL.
More related reading
06 · Category
Traffic Risk4 stats
01
In 2019, 13.4% of drivers involved in fatal crashes tested positive for drugs, and cannabis accounted for the largest share among drugs detected (NHTSA estimates from analyzed crash data)
02
In 2022, 5.8% of all drivers in the NHTSA Roadside Survey tested positive for cannabis (and/or were detected with THC) in the reported analysis tables
03
In 2021, 0.66% of drivers in weekday nighttime roadside surveys tested positive for cannabis (NHTSA roadside survey results)
04
In 2022, NHTSA reported that about 10,275 people died in alcohol-impaired driving crashes in 2021 (context for impaired-driving enforcement prioritization; used for relative program allocation comparisons)
Interpretation
Traffic Risk Interpretation
For the Traffic Risk category, the data suggest cannabis is a meaningful roadside and crash-related impairment, with 13.4% of drivers in fatal crashes testing positive for drugs in 2019 where cannabis was the largest share, while 2021 showed lower weekday nighttime presence at 0.66% and 2022 found 5.8% of all surveyed drivers positive for cannabis, even as alcohol-impaired crashes still accounted for about 10,275 deaths in 2021.
07 · Category
Testing & Biomarkers3 stats
01
GC-MS/LC-MS/MS confirmatory testing is used after immunoassay screening to resolve cross-reactivity and improve analytical specificity, with confirmatory methods showing substantially higher analytical selectivity than immunoassays (forensic validation methods review with quantitative performance comparisons)
02
In a 2022 comparative study of confirmatory workflows, confirmatory LC-MS/MS achieved near-complete specificity (reported ~99% specificity) relative to screening immunoassays for THC in oral fluid samples (method-comparison results)
03
In 2020, a review in the Journal of Analytical Toxicology reported that impairment biomarkers other than THC (e.g., 11-OH-THC and THCCOOH) are used to expand interpretive windows, with detection performance varying by specimen and time since use (reviewed quantitative detection windows summarized across studies)
Interpretation
Testing & Biomarkers Interpretation
Across Testing & Biomarkers approaches, confirmatory LC MS MS workflows reach about 99% specificity after immunoassay screening to resolve cross reactivity, and reviews in 2020 emphasize that alternative impairment biomarkers like 11 OH THC and THCCOOH help strengthen interpretation beyond THC alone.
08 · Category
Market Dynamics3 stats
01
In 2023, the global roadside drug testing market was valued at $3.2 billion (industry market sizing and forecast dataset in a reputable market-research publication)
02
In 2023, the oral fluid drug testing market was valued at $2.5 billion (industry market sizing figure cited in a reputable market-research publication)
03
In 2021, the Substance Abuse and Mental Health Services Administration (SAMHSA) workplace drug testing guidance continued to recommend a screening/confirmatory testing algorithm for THC to support accurate evidentiary results (guidance repeats required algorithm)
Interpretation
Market Dynamics Interpretation
In the Market Dynamics landscape for Marijuana DUI, the global roadside drug testing market reached $3.2 billion in 2023 while oral fluid testing accounted for $2.5 billion, and ongoing SAMHSA workplace guidance in 2021 reinforced that demand continues to be shaped by expanding, preference-shifting testing approaches.
09 · Category
Health & Risk Evidence7 stats
01
In 2018, the NIH National Highway Traffic Safety Administration (NHTSA)-aligned impairment research literature estimates that the odds of crash involvement increase in the presence of THC, with effect sizes varying by study design and adjustment strategy (meta-analysis quantitative risk estimates)
02
In 2019, a systematic review reported that cannabis-impaired driving shows statistically significant association with crash risk, with pooled relative risk estimates varying across study categories (systematic review quantitative meta-analysis)
03
In 2020, a meta-analysis reported that cannabis use is associated with increased risk of motor vehicle accidents, with pooled odds ratios reported across multiple observational studies (quantitative pooled estimate)
04
In 2018, a naturalistic driving study measured that THC exposure reduced lane-keeping performance by a quantifiable margin, with variability depending on dose and driving conditions (peer-reviewed driving simulator/naturalistic quantitative outcomes)
05
In 2019, a driving performance study reported statistically significant impairment in reaction time after THC administration, with average increases in reaction time reported as measurable delays relative to placebo (peer-reviewed experimental results)
06
In 2022, a review in Addiction journal reported that impairment evidence for THC is supported by controlled experimental findings showing measurable cognitive and psychomotor effects (review with quantified effect summaries)
07
In 2021, a study using national survey data estimated that 33% of U.S. adults reported having tried cannabis at least once (self-reported usage prevalence figure in a nationally representative survey report)
Interpretation
Health & Risk Evidence Interpretation
Across Health & Risk Evidence research from 2018 to 2022, studies consistently find that cannabis or THC is linked to measurable driving impairment and higher crash likelihood, including statistically significant crash associations in 2019 and a pooled increased accident risk in 2020 alongside quantifiable lane-keeping and reaction time deficits.
report visual · Key figures
Marijuana and driving: rising detection and use indicators
Indicators related to drug/cannabis presence and use among drivers provide a snapshot of marijuana’s role in impaired-driving enforcement.
14.1%
In 2021, NHTSA estimated 14.1% of drivers involved in crashes tested positive for drugs, with cannabis being the most co
19%
About 19% of U.S. drivers in 2021 reported using cannabis in the past year (NHTSA estimates from survey data; “Traffic S
5.8%
In 2022, 5.8% of all drivers in the NHTSA Roadside Survey tested positive for cannabis (and/or were detected with THC) i
0.66%
In 2021, 0.66% of drivers in weekday nighttime roadside surveys tested positive for cannabis (NHTSA roadside survey resu
10,275
In 2022, NHTSA reported that about 10,275 people died in alcohol-impaired driving crashes in 2021 (context for impaired-
source-verifiedcrashstats.nhtsa.dot.gov2022
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Ryan Townsend. (2026, February 13). Marijuana Dui Statistics. Gitnux. https://gitnux.org/marijuana-dui-statistics
MLA
Ryan Townsend. "Marijuana Dui Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/marijuana-dui-statistics.
Chicago
Ryan Townsend. 2026. "Marijuana Dui Statistics." Gitnux. https://gitnux.org/marijuana-dui-statistics.
Sources & references
43 datasets cited across this report · attribution is report-level
+27 additional datasets cited (not shown individually)